Correspondence 0000950170-24-003995 from Evoke Pharma Inc (EVOK) (CIK 0001403708)
Evoke Pharma Inc (EVOK) (CIK 0001403708)
Date: Jan. 11, 2024 · CIK: 0001403708 · Accession: 0000950170-24-003995
AI Filing Summary & Sentiment
File numbers found in text: 333-275443
Letter
Re: Evoke Pharma, Inc.
Evoke Pharma, Inc.
420 Stevens Avenue, Suite 230
Solana Beach, CA 92075
January 11, 2024
VIA EDGAR
Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549
Registration Statement on Form S-1, as amended
File No. 333-275443
To the addressees set forth above:
Reference is made to the letter from Evoke Pharma, Inc. (the “Company”), filed as correspondence via EDGAR on January 5, 2023, in which the Company requested that the effective date of the Registration Statement on Form S-1 referred to above (the “Registration Statement”) be accelerated so that it would become effective at 4:00 P.M. Eastern Time on January 9, 2023, or as soon as practicable thereafter (the “Effective Time”), pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended.
The Company no longer requests that such Registration Statement be declared effective at the Effective Time, and the Company hereby withdraws its request for the acceleration of the effective date until providing further notice.
If you have any questions regarding the foregoing, please do not hesitate to contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969.
Very truly yours,
EVOKE PHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Evoke Pharma, Inc. 420 Stevens Avenue, Suite 230 Solana Beach, CA 92075 January 11, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Evoke Pharma, Inc. Registration Statement on Form S-1, as amended File No. 333-275443 To the addressees set forth above: Reference is made to the letter from Evoke Pharma, Inc. (the “Company”), filed as correspondence via EDGAR on January 5, 2023, in which the Company requested that the effective date of the Registration Statement on Form S-1 referred to above (the “Registration Statement”) be accelerated so that it would become effective at 4:00 P.M. Eastern Time on January 9, 2023, or as soon as practicable thereafter (the “Effective Time”), pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended. The Company no longer requests that such Registration Statement be declared effective at the Effective Time, and the Company hereby withdraws its request for the acceleration of the effective date until providing further notice. If you have any questions regarding the foregoing, please do not hesitate to contact Anthony Gostanian of Latham & Watkins LLP, counsel to the Company, at (858) 523-3969. Very truly yours, EVOKE PHARMA, INC. By: /s/ David A. Gonyer David A. Gonyer Chief Executive Officer |US-DOCS\147668126.2|| cc: Matthew J. D’Onofrio, Evoke Pharma, Inc. Matthew T. Bush, Latham & Watkins LLP Anthony Gostanian, Latham & Watkins LLP Richard A. Friedman, Sheppard, Mullin, Richter & Hampton LLP |US-DOCS\147668126.2||